NCT07463872 Management of Pancreatic Cystic Lesions Using Artificial Intelligence Based on EUS and Multimodal Data
| NCT ID | NCT07463872 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Huazhong University of Science and Technology |
| Condition | Pancreatic Cystic Lesion |
| Study Type | OBSERVATIONAL |
| Enrollment | 500 participants |
| Start Date | 2025-01-01 |
| Primary Completion | 2026-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 500 participants in total. It began in 2025-01-01 with a primary completion date of 2026-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The primary objective is to construct a multimodal AI model (Cyst-AI) based on EUS images and clinical data such as imaging features(CT or MRI) and laboratory tests to assist endoscopists in the diagnosis of pancreatic cystic lesions(PCLs), mainly differentiating mucinous from non-mucinous lesions. The secondary objective is to evaluate the model's effectiveness in risk stratification and clinical management for patients with PCLs.
Eligibility Criteria
Inclusion criteria: * Patients whose EUS results indicates pancreatic cystic or cystoid lesions; * Mucinous lesions: including mucinous cystic neoplasm (MCN), intraductal papillary mucinous neoplasm (IPMN); * Non-mucinous lesions: including pancreatic pseudocyst, serous cystic neoplasm (SCN), cystic neuroendocrine tumor (cNET). Exclusion criteria: * Patients whose age is less than 18 years old; * Patients who have undergone pancreatic surgery before the EUS examination; * Patients who have received chemotherapy and radiotherapy for pancreatic tumors before the EUS examination; * Pathological results indicate that pancreatic lesions are metastatic lesions from other sites; * Patients whose EUS images or reports are missing; * EUS image quality does not meet the requirements for review, such as blurry imaging or containing artifacts, biopsy needles, measuring scales, or other additional annotations that are not part of the original EUS image; * Patients whose final diagnosis is unclear.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07463872 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Pancreatic Cystic Lesion. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07463872 currently recruiting?
Yes, NCT07463872 is actively recruiting participants. Contact the research team at b.cheng@tjh.tjmu.edu.cn for enrollment information.
Where is the NCT07463872 trial being conducted?
This trial is being conducted at Wuhan, China, Wuhan, China.
Who is sponsoring the NCT07463872 clinical trial?
NCT07463872 is sponsored by Huazhong University of Science and Technology. The trial plans to enroll 500 participants.